Company BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-18 EDT 5-day change 1st Jan Change
2.55 USD -1.54% Intraday chart for BioXcel Therapeutics, Inc. -8.60% -13.56%

Business Summary

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Number of employees: 74

Sales per Business

USD in Million2022Weight2023Weight Delta
Neuroscience and Immuno-oncology Drugs
100.0 %
0 100.0 % 1 100.0 % +268.00%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 1 100.0 % +268.00%

Managers

Managers TitleAgeSince
Founder 63 17-03-28
Director of Finance/CFO 66 17-09-30
Chief Tech/Sci/R&D Officer 68 17-05-31
Chief Tech/Sci/R&D Officer 55 17-06-30
Investor Relations Contact - -
General Counsel - -
Corporate Officer/Principal 52 22-01-18
General Counsel 52 21-02-22
55 -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 22-06-30
Chairman 68 17-03-31
Director/Board Member 56 17-08-31
Founder 63 17-03-28
55 -
Director/Board Member 58 19-03-06
Director/Board Member 70 21-02-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,436,513 24,404,073 ( 72.99 %) 0 72.99 %

Shareholders

NameEquities%Valuation
BioXcel Corp.
25.41 %
8,546,750 25.41 % 24 M $
Fidelity Management & Research Co. LLC
7.489 %
2,518,564 7.489 % 7 M $
BlackRock Advisors LLC
3.935 %
1,323,404 3.935 % 4 M $
Vanguard Fiduciary Trust Co.
3.239 %
1,089,463 3.239 % 3 M $
Columbia Management Investment Advisers LLC
1.609 %
541,064 1.609 % 2 M $
Adage Capital Partners GP LLC
1.384 %
465,381 1.384 % 1 M $
Geode Capital Management LLC
1.339 %
450,227 1.339 % 1 M $
440,332 1.309 % 1 M $
Beacon Pointe Advisors LLC
0.8972 %
301,735 0.8972 % 850 893 $
232,597 0.6916 % 655 924 $

Company contact information

BioXcel Therapeutics, Inc.

555 Long Wharf Drive 12th floor

06511, New Haven

+475 238 6837

http://www.bioxceltherapeutics.com
address BioXcel Therapeutics, Inc.(BTAI)
  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. Company BioXcel Therapeutics, Inc.